Patents by Inventor Lucian V. DiPietro

Lucian V. DiPietro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20250090540
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K? enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K? signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: September 9, 2022
    Publication date: March 20, 2025
    Inventors: Alessandro BOEZIO, Alexander M. TAYLOR, Hakan GUNAYDIN, Hanmo ZHANG, Kevin David RAYNOR, Kelley C. SHORTSLEEVES, Lucian V. DIPIETRO, Levi Charles Thomas PIERCE, Nicolas PABON, Thomas H. MCLEAN, Fabrizio GIORDANETTO, Yakov PECHERSKY, Qi WANG, Alexandre LARIVEE, Fei CHEN, Gaetan MAERTENS, Johanne OUTIN, Megan BERTRAND-LAPERLE, Mohan PAL, Sampada CHITALE, Michael Paul DENINNO
  • Substituted isoindolines as PI3K-alpha inhibitors
    Patent number: 12219327
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K-? enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K-? signaling with the compounds and compositions of the disclosure.
    Type: Grant
    Filed: June 9, 2023
    Date of Patent: February 4, 2025
    Assignees: Relay Therapeutics, Inc., D. E. Shaw Research, LLC
    Inventors: Lucian V. Dipietro, Kelley C. Shortsleeves, Thomas H. Mclean, Alexandre Larivee, Fabrizio Giordanetto, André Lescarbeau, Alessandro Boezio, Hanmo Zhang
  • PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20250019380
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K? enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K? signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: July 13, 2022
    Publication date: January 16, 2025
    Inventors: Alessandro BOEZIO, Alexander M. TAYLOR, Cary Griffin FRIDRICH, Hakan GUNAYDIN, Lucian V. DIPIETRO, Levi Charles Thomas PIERCE, Mary M. MADER, Ravi KURUKULASURIYA, Thomas H. MCLEAN, Yue PAN, Michael Paul DENINNO, Alexandre LARIVEE, Andrew j. BURNIE, Caleb MEDENA, Gaetan MAERTENS, Kashif TANVEER, Mohan PAL, Tarek MOHAMED, Thomas LEPITRE, Bren-Jordan ATIENZA, Naresh VEMULA, Shorena GELOZIA
  • INHIBITORS OF RET
    Publication number: 20240417386
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: January 25, 2024
    Publication date: December 19, 2024
    Inventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
  • JAK2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240368122
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of JAK2 enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with JAK2 signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: August 19, 2022
    Publication date: November 7, 2024
    Inventors: Lucian V. DiPietro, Ravi Kurukulasuriya, Amael Madec, Catherine A. Evans, Cary Griffin Fridrich, Rebecca Jane Swett, Alessandro Boezio, Alexander M. Taylor, Thomas H. McLean, Christopher Thomson
  • PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240287058
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K-? enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K-? signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: April 29, 2021
    Publication date: August 29, 2024
    Inventors: Alessandro BOEZIO, Lucian V. DIPIETRO, Cary Griffin FRIDRICH, Hakan GUNAYDIN, Ravi KURUKULASURIYA, André LESCARBEAU, Mary M. MADER, Thomas H. MCLEAN, Levi CharlesThomas PIERCE, Kevin David RAYNOR, Kelley C. SHORTSLEEVES, Yong TANG, Alexander M. TAYLOR, W. Patrick WALTERS, Hanmo ZHANG, Fabrizio GIORDANETTO, Yakov PECHERSKY, Qi WANG, Bren-Jordan ATIENZA, Megan BERTRAND-LAPERLE, Andrew J. BURNIE, Fei CHEN, Sampada CHITALE, Shorena GELOZIA, Jean-Benoit GIGUERE, Elodie LANDAGARAY, Alexandre LARIVEE, Thomas LEPITRE, Gaetan MAERTENS, Johanne OUTIN, Mohan PAL, Claudio STURINO, Kashif TANVEER, Rakesh THORAT, Naresh VEMULA, Elaine B. KRUEGER, Yue PAN, Michael Paul DENINNO, Yves BOUSQUET, Antoine JOBIN-DES LAURIERS, Jessica LEE, Tarek MOHAMED
  • PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230353959
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K-? enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K-? signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: June 9, 2023
    Publication date: November 2, 2023
    Inventors: Lucian V. DIPIETRO, Kelley C. SHORTSLEEVES, Thomas H. MCLEAN, Alexandre LARIVEE, Fabrizio GIORDANETTO
  • SHP2 phosphatase inhibitors and methods of use thereof
    Patent number: 11629145
    Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds ad compositions of the invention.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: April 18, 2023
    Assignees: D. E. Shaw Research, LLC, Relay Therapeutics, Inc.
    Inventors: Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Alexander M. Taylor, Lucian V. Dipietro, Elizabeth H. Kelley, André Lescarbeau, Mark Andrew Murcko, Levi Charles Thomas Pierce, Kelley C. Shortsleeves, W. Patrick Walters, Sathesh Bhat, Eric Therrien, Markus Kristofer Dahlgren
  • Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
    Patent number: 11591336
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions thereof and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: February 28, 2023
    Assignees: D. E. Shaw Research, LLC, Relay Therapeutics, Inc.
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, Lucian V. DiPietro, W. Patrick Walters, Mark Andrew Murcko, Levi Charles Thomas Pierce, Yong Tang, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Sathesh Bhat, Markus Kristofer Dahlgren, Eric Therrien
  • INHIBITORS OF RET
    Publication number: 20220315560
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: February 11, 2022
    Publication date: October 6, 2022
    Inventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
  • Inhibitors of RET
    Patent number: 11279688
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: March 22, 2022
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
  • INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
    Publication number: 20210347756
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: November 24, 2020
    Publication date: November 11, 2021
    Inventors: Neil Bifulco, JR., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
  • INHIBITORS OF RET
    Publication number: 20200407341
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: January 29, 2020
    Publication date: December 31, 2020
    Inventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
  • Inhibitors of the fibroblast growth factor receptor
    Patent number: 10875837
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: December 29, 2020
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Neil Bifulco, Jr., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
  • 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
    Patent number: 10774070
    Abstract: Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: September 15, 2020
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Natasja Brooijmans, Lucian V. DiPietro, Paul E. Fleming, Joseph L. Kim, Steven Mark Wenglowsky, Yulian Zhang
  • PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS
    Publication number: 20200172546
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure.
    Type: Application
    Filed: May 25, 2018
    Publication date: June 4, 2020
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, Lucian V. DiPietro, W. Patrick Walters, Mark Andrew Murcko, Levi Charles Thomas Pierce, Yong Tang, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Sathesh Bhat, Markus Kristofer Dahlgren, Eric Therrien
  • INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
    Publication number: 20200109127
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: February 19, 2019
    Publication date: April 9, 2020
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Neil Bifulco, JR., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
  • Inhibitors of RET
    Patent number: 10584114
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: March 10, 2020
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
  • SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20200062760
    Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds ad compositions of the invention.
    Type: Application
    Filed: October 24, 2017
    Publication date: February 27, 2020
    Inventors: Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Alexander M. Taylor, Lucian V. Dipietro, Elizabeth H. Kelley, André Lescarbeau, Mark Andrew Murcko, Levi Charles Thomas Pierce, Kelley C. Shortsleeves, W. Patrick Walters, Sathesh Bhat, Eric Therrien, Markus Kristofer Dahlgren
  • 2-(PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES AS RET INHIBITORS
    Publication number: 20190359591
    Abstract: Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g.
    Type: Application
    Filed: December 20, 2018
    Publication date: November 28, 2019
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Natasja BROOIJMANS, Lucian V. DIPIETRO, Paul E. FLEMING, Joseph L. KIM, Steven Mark WENGLOWSKY, Yulian ZHANG